key: cord-1013774-65gedo6u
authors: Seet, Raymond Chee Seong; Quek, Amy May Lin; Ooi, Delicia Shu Qin; Sengupta, Sharmila; Lakshminarasappa, Satish Ramapatna; Koo, Chieh Yang; So, Jimmy Bok Yan; Goh, Boon Cher; Loh, Kwok Seng; Fisher, Dale; Teoh, Hock Luen; Sun, Jie; Cook, Alex R.; Tambyah, Paul Anantharajah; Hartman, Mikael
title: Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial
date: 2021-04-20
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.04.035
sha: bef8b0973aeb8693489541d1d6ca11326ff65eb9
doc_id: 1013774
cord_uid: 65gedo6u

Background We examined whether existing licensed pharmacotherapies could reduce the spread of coronavirus disease 2019 (COVID-19). Methods An open-label parallel randomized controlled trial was performed among healthy migrant workers quarantined in a large multi-storey dormitory in Singapore. Forty clusters (each defined as individual floors of the dormitory) were randomly assigned to receive a 42-day prophylaxis regimen of either oral hydroxychloroquine (400 mg once, followed by 200 mg/day), oral ivermectin (12 mg once), povidone-iodine throat spray (3 times/day, 270 µg/day), oral zinc (80 mg/day)/vitamin C (500 mg/day) combination, or oral vitamin C, 500 mg/day. The primary outcome was laboratory evidence of SARS-CoV-2 infection as shown by either: (1) a positive serologic test for SARS-CoV-2 antibody on day 42, or (2) a positive PCR test for SARS-CoV-2 at any time between baseline and day 42. Results A total of 3,037 asymptomatic participants (mean age, 33.0 years; all men) who were seronegative to SARS-CoV-2 at baseline were included in the primary analysis. Follow-up was nearly complete (99.6%). Compared with vitamin C, significant absolute risk reductions (%, 98.75% confidence interval) were observed for oral hydroxychloroquine (21%, 2–42%) and povidone-iodine throat spray (24%, 7–39%). No statistically significant differences were observed with oral zinc/vitamin C combination (23%, –5 to +41%) and ivermectin (5%, –10 to +22%). Interruptions due to side effects were highest among participants who received zinc/vitamin C combination (6.9%), followed by vitamin C (4.7%), povidone-iodine (2.0%) and hydroxychloroquine (0.7%). Conclusions Chemoprophylaxis with either oral hydroxychloroquine or povidone-iodine throat spray was superior to oral vitamin C in reducing SARS-CoV-2 infection in young and healthy men. ClinicalTrials.gov number NCT04446104

followed by 200mg/day), oral ivermectin (12mg once), povidone-iodine throat spray (3 times/day, 270 µg/day), oral zinc (80mg/day)/vitamin C (500mg/day) combination, or oral vitamin C, 500mg/day. The primary outcome was laboratory evidence of SARS-CoV-2 infection as shown by either: (1) a positive serologic test for SARS-CoV-2 antibody on day 42, or (2) a positive PCR test for SARS-CoV-2 at any time between baseline and day 42.

Results: A total of 3,037 asymptomatic participants (mean age, 33.0 years; all men) who were seronegative to SARS-CoV-2 at baseline were included in the primary analysis.

Follow-up was nearly complete (99.6%). Compared with vitamin C, significant absolute risk reductions (%, 98.75% confidence interval) were observed for oral hydroxychloroquine (21%, 2-42%) and povidone-iodine throat spray (24%, 7-39%). No statistically significant differences were observed with oral zinc/vitamin C combination (23%, -5 to +41%) and ivermectin (5%, -10 to +22%). Interruptions due to side effects were highest among participants who received zinc/vitamin C combination (6.9%), followed by vitamin C (4.7%), povidone-iodine (2.0%) and hydroxychloroquine (0.7%).

Chemoprophylaxis with either oral hydroxychloroquine or povidone-iodine throat spray was superior to oral vitamin C in reducing SARS-CoV-2 infection in young and healthy men. while targeted quarantine limits movement of identified contacts. [1] [2] [3] Notwithstanding, the outbreak has been challenging to contain, as new case clusters continued to emerge and even surged in numbers even after the initial quarantine measures. A pharmacological agent effective in preventing COVID-19 would be a useful adjunct to NPIs, especially in a setting of uncontrolled transmission. Two antiparasitic drugs (hydroxychloroquine 5-7 and ivermectin 7, 8 ) have been shown to reduce affinity of SARS-CoV-2 to the angiotensinconverting-enzyme 2 receptors in vitro. Hydroxychloroquine inhibits SARS-CoV-2 infection of Vero cells by elevating endosomal pH, 5, 6 while ivermectin binds to Impα/β1 heterodimer to inhibit SARS-CoV-2 replication. 8 The antiseptic povidone-iodine has rapid virucidal effects against SARS-CoV-2, 9, 10 while zinc inhibits replication of at least six coronaviruses (including SARS-CoV and others that cause common colds). 11, 12 Despite a lack of preclinical evidence of efficacy against coronaviruses, vitamin C is a widely used remedy during this pandemic. 13 Beginning April 2020, Singapore witnessed a surge in COVID-19 cases following widespread outbreaks in residential dormitories of migrant workers, prompting strict J o u r n a l P r e -p r o o f lockdown measures in an attempt to contain virus transmission and to reduce spillover into the general population. 3,14-17 As of 5 March 2021, more than 90% of 59,998 reported cases in Singapore involved migrant workers. 18 Efforts to isolate and quarantine infected workers have been challenging given the high population density in the dormitories. 6, 14 We hypothesized that at least one pharmacologic agent (hydroxychloroquine, ivermectin, povidone-iodine, zinc/vitamin C combination, or vitamin C) could be efficacious as prophylaxis against SARS-CoV-2 among individuals living in a closed and high exposure setting.

This study was an open-label, parallel randomized clinical trial to evaluate the efficacy of oral hydroxychloroquine, oral ivermectin, povidone-iodine throat spray, oral zinc/vitamin C combination and oral vitamin C for SARS-CoV-2 prophylaxis. Subjects were randomized in clusters with each cluster defined by the residential floor of a multistorey 

All dormitory residents aged between 21 and 60 years who were willing to adhere to the study protocol, return for a review 42-days later, and provide daily symptom feedback through a mobile application, were invited to participate in this trial. Participants were excluded if they had symptom(s) of respiratory illnesses (fever, cough, runny nose, sore throat and/or shortness of breath), dysgeusia or anosmia in the past one month, had a previous diagnosis of COVID-19, or met other exclusion criteria (Supplementary Materials).

Recruitment was performed at Tuas South Dormitory, Singapore. The dormitory complex contains 5 residential buildings, each with 9 floors and equal number of rooms per floor; not all rooms were fully occupied during the study. Each room is divided into different J o u r n a l P r e -p r o o f sections housing double-decker beds, communal dining, wash areas and 2 en suite shared bathrooms. At capacity, up to 14 men could reside in the larger rooms (approx. 72 sq m) and up to 10 men in the smaller rooms (approx. 60 sq m) (maximum density, 5.15-6.00 sq m per person). The outbreak in this dormitory was part of a larger outbreak involving migrant workers in Singapore linked to a large hypermarket frequented by these workers. 16 Unlinked cases were detected sporadically in different blocks and floors with no discernable pattern, and the index case(s) could not be epidemiologically identified in this dormitory. The dormitory was gazetted as an isolation area under Singapore's Infectious Diseases Act on 23 April 2020 after the first case was identified at Tuas South Dormitory on 7 April 2020. Enrolment into the trial began on 18 May 2020 and a recruitment window of 14 days was set to include as many uninfected participants as possible. As part of enhanced surveillance, dormitory residents were all closely monitored and underwent nasopharyngeal swabs for SARS-CoV-2 PCR whenever they developed respiratory symptoms or were roommates of those with respiratory symptoms, to facilitate early isolation. 19 A medical team (comprising doctors and nurses) was present on-site daily to attend to the medical needs of the dormitory residents and to perform nasopharyngeal swabs throughout the quarantine. On the day of first enrolment, 346 PCR positive cases had been identified and were transferred to off-site isolation facilities. As part of gazetting regulations, resident movements were strictly restricted by law.

Interactions among residents living in different rooms, floors, and blocks were not permitted; these measures were reinforced by barriers set up between blocks and 24/7 security personnel. Residents were not permitted to leave the dormitories except for medical care under escort and shared cooking facilities were closed. Food was J o u r n a l P r e -p r o o f individually packed and catered to their dietary preferences with utensils provided with instructions not to share utensils. One representative from each room would collect individually packed food 3 times daily at assigned schedules. NPIs enforced included mandatory mask wearing and regular messaging encouraging social distancing, hand hygiene and environmental cleaning. Within rooms, residents were asked to wear masks and encouraged to frequently wash their hands, although these measures were not enforceable within rooms out of sight of security personnel. These measures continued throughout the study period. The trial was first publicized to residents a week prior to trial initiation through the public address system, room-to-room visits by study investigators, On the day of recruitment, contents of the informed consent form were read and explained in English and the worker's native languages by trained interpreters, before written informed consent was obtained from individual participants. Information on demography (age and gender), country of origin, and medical history were obtained by direct interview and entered using FormSG, an encrypted tool developed by Singapore's GovTech Data Science & Artificial Intelligence Capability Centre. Body weight, height, blood pressure and heart rate were measured in all participants. Each room was graded according to the risk of SARS-CoV-2 exposure; unexposed rooms had no identified confirmed COVID-19 cases at any time prior to randomization. Participants were asked J o u r n a l P r e -p r o o f to report their symptoms daily using FormSG. Each participant was given a mobile number to contact the study team by phone call or SMS throughout the study. In consultation with the Singapore regulators, additional safety measures were added following adverse safety reports arising from the use of hydroxychloroquine for COVID-19 treatment. 20 A 12-lead electrocardiogram was performed in all participants randomized to receive hydroxychloroquine. Participants with the following electrocardiogram and blood pressure/heart rate findings were excluded from hydroxychloroquine prophylaxis: corrected QT interval exceeding 450 ms, any arrhythmia (including benign ones e.g.

premature atrial or ventricular complexes), left ventricular hypertrophy, left bundle branch block, systolic blood pressure >140mmHg, diastolic blood pressure >85mmHg and heart rate >100 per min.

Blood samples were collected from all participants at randomization and 42 days later; extracted sera were analysed for antibody response to SARS-CoV-2 using the Elecsys® anti-SARS-CoV-2 antibody test (Roche, Germany). Results of participants who underwent nasopharyngeal swabs for SARS-CoV-2 RNA detection by quantitative RT-PCR method 19 were retrieved from medical records to ascertain status of SARS-CoV-2 infection.

After randomization, each participant was supplied with a 42-day supply of the assigned intervention (except for ivermectin that was administered as a single dose) and was responsible for taking the medication as instructed without further direct supervision or observation by the study team. Hydroxychloroquine was sourced as hydroxychloroquine J o u r n a l P r e -p r o o f sulfate from Shanghai Pharmaceuticals Holding Co., Ltd in 100mg tablets, ivermectin from Edenbridge Pharmaceuticals LLC as 3mg tablets, povidone-iodine as povidoneiodine 0.45% (Betadine®) from Mundipharma Pte Ltd, zinc was sourced as zinc oxide 40mg in combination with vitamin C 250mg (Macu-Vision®) from Blackmores Ltd and vitamin C in 500mg tablets also from Blackmores Ltd. The dosing regimen of hydroxychloroquine sulfate was 400mg (4 tablets) once, followed by 200mg (2 tablets) daily for 42 days. Although pharmacokinetic studies suggested a higher dosage of ivermectin (50-to 100-fold higher than approved limits) may be necessary to inhibit SARS-CoV-2 replication, 8 sparse human data are available to support safety and efficacy of ivermectin against SARS-CoV-2 at these doses. Given these uncertainties, we kept the dosage of ivermectin to within the approved limits of 200µg/kg; a single dose of 12mg was administered in participants who weighed >60kg. Povidone-iodine throat spray was self-administered 3 times daily (approximately 270 µg/day) for 42 days. Zinc (40mg) was administered in combination with vitamin C (250mg) twice daily (total, zinc 80mg and vitamin C 500mg/day) while Vitamin C (500mg) was administered once daily. The first dose of hydroxychloroquine (400mg) or ivermectin (12mg) was consumed in the presence of the study team. On day 42, participants were asked to grade their medication adherence on a score of 0 to 10 (where 0=non-adherence and 10=full adherence) which was verified by counting the number of remaining pills. Temasek Foundation, a Singapore-based philanthropic organization, donated hydroxychloroquine and ivermectin, Mundipharma Pte Ltd donated the povidone-iodine throat spray, while Blackmores Ltd donated zinc/vitamin C and vitamin C tablets used in this study. None of these organizations had any input into the study design or analysis. 

The original sample size calculation was based on individual randomization which prioritized the number of participants. We had initially estimated a sample size of 550 subjects would need to be enrolled in each prophylaxis arm to detect a 20% difference between intervention and control groups with a power of 80% and α=0.0125 (adjusted for multi-intervention comparisons by Bonferroni's methods). By assuming 10% seropositivity at baseline and 10% rate of attrition, we projected a minimum sample size of 660 participants per arm. These calculations, however, did not consider cluster randomization which was the only practical option based on the situation on the ground.

Using sample size that was initially projected per arm based on the expected effect, 8 clusters per arm (as the number of floors available for randomization was fixed) with J o u r n a l P r e -p r o o f cluster sizes of 75 subjects, and an intracluster correlation of ρ=0.1 (as observed in the actual study), the retrospective power of the study to detect an absolute difference in risk of 0.3 was ~70%; the conditional power for povidone-iodine and hydroxychloroquine versus vitamin C was 99% and 85%, respectively (Supplementary Materials).

Each room was ordered sequentially numbered by block and floor, and imported into statistical computer software Stata V.16 which randomly allocated floors to interventions and control prior to study initiation. Information on cluster allocation was concealed by a study statistician who informed the study team of the assigned intervention and floor a day prior to recruitment to facilitate preparations.

We excluded those seropositive at baseline. We assessed laboratory-confirmed SARS-CoV-2 infection between intervention groups using logistic regression methods with random effects to accommodate clustering, deriving derived odds ratios (with 98.75% confidence intervals to accommodate multiple testing) and Wald p-values. Bootstrap 98.75% confidence intervals for the absolute and relative risk differences compared to Vitamin C were derived by bootstrapping at the cluster-level. In secondary analysis we adjusted for exposure to cases in the same room at the point of recruitment, as this modulated the risk in exploratory analysis. Cumulative incidence of SARS-CoV-2 infection across time was assessed using PCR-confirmed infection that occurred before the end J o u r n a l P r e -p r o o f of active follow up were considered to have the event. Those without a PCR test, or with a negative PCR but who continued in the study, were censored at the end of active follow up, approximately 42 days after enrollment, when serology was taken, or until an event occurred. Otherwise, the individual was censored at the end of active follow up. To address multiple testing arising from having four other intervention arms that we compared against Vitamin C, a Bonferroni-corrected level of α=0.0125 was used to determine statistical significance. All statistical analyses used R. 21

Of the 45 available floors, 3 floors were repurposed as dedicated isolation facilities for identified cases before they were relocated offsite for appropriate care; the remaining 42 floors ("clusters") were available for randomization. Of these, 40 floors were randomly selected and assigned in equal ratios to receive the trial interventions (Fig. 1) . Two floors were reserved to balance the sample size in each prophylaxis arm; these contingency measures were necessary as there were initial uncertainties on the residents' willingness to participate in a clinical trial. To achieve the sample size targets, men from these two non-randomized floors were recruited into the different arms, and those who did not fulfill the body weight criteria for ivermectin and the blood pressure and heart rate criteria for hydroxychloroquine were assigned to receive vitamin C. A total of 5,255 out of 6,502 men residing in the dormitory were evaluated for study eligibility; 1,247 men declined to participate. A total of 998 men were excluded as they did not meet the eligibility criteria ( Fig. 1) . Of the 4,257 men who were recruited, data from 849 men who were recruited from non-randomized floors (including those who received vitamin C but recruited from hydroxychloroquine and ivermectin-assigned floors) (Supplementary Materials, Table S1) and men who were found to be seropositive to SARS-CoV-2 on recruitment (n=359) were excluded from the primary analysis. Baseline seropositive rates per cluster were hydroxychloroquine 10.0%, ivermectin 12.4%, povidone-iodine 14.5%, zinc/vitamin C 8.1%

and vitamin C 6.3%. Twelve men withdrew and 3,037 men completed the 42-day study (retention rate 99.6%).

The primary cohort comprised 3,037 men (mean age, 33.0 years, mostly from India and Bangladesh) who received hydroxychloroquine (n=432), ivermectin (n=617), povidone-iodine (n=735), zinc/vitamin C combination (n=634), and vitamin C (n=619) ( Table 1) (Table 2) . Compared with vitamin C, significant absolute risk reductions (%, 98.75% confidence interval) were observed for oral hydroxychloroquine (21%, 2-42%) and povidone-iodine throat spray (24%, 7-39%) ( Table 3) . No statistically significant absolute risk reductions were observed with zinc/vitamin C combination (23%, -5 to +46%) and ivermectin (5%, -10 to +22%). Reduction in the incidence of SARS-CoV-2 infection in the hydroxychloroquine and povidone-iodine throat spray groups remained statistically significant after adjustments were made for potential confounders (previous room exposure, age categories, nationalities, compliance to medications and baseline seropositivity within the same cluster) ( (Table S3 and Fig. S1 ) after accounting for clustering, though the direction and magnitude of effect sizes were consistent with the primary endpoint. To interrogate the primary outcome further, additional analyses were performed to investigate the potential impact of medication adherence on SARS-CoV-2 infection according to the different groups.

Consistently, men with greater medication adherence were significantly less likely to be infected (Supplementary Materials, Table S4 and Fig. S2 ).

Adherence among the trial participants was moderately good with 80% grading their adherence as 7 or more (on a scale of 10). Apart from the ivermectin group (where intake was directly observed), adherence was highest in the povidone-iodine group (88%) and lowest in the hydroxychloroquine group (71%) ( Table 5) . Interruptions due to side effects were highest among men who received zinc/vitamin C combination (6.9%), followed by vitamin C (4.7%), povidone-iodine (2.0%) and hydroxychloroquine (0.7%). Noteworthy, the lower adherence to hydroxychloroquine was attributed mainly to concerns of potential side effects (12%) and personal decisions (3%), than for actual side effects. Men in the povidone-iodine group were least symptomatic (14%) compared with the other interventions (hydroxychloroquine 20%, ivermectin 22%, zinc/vitamin C combination 18% and vitamin C 20%, p=0.003); fewer in the povidone-iodine group complained of headaches, loss of appetite and constipation (Table 4 ). Among men who received hydroxychloroquine, corrected QT interval did not statistically significantly differ between baseline and follow-up readings (mean, 379 vs 378 ms, respectively; paired t-test, p=0.387).

In this open-label randomized clinical trial, short-term use of either oral hydroxychloroquine or povidone-iodine throat spray was found to be superior to vitamin C in lowering the incidence of laboratory-confirmed SARS-CoV-2 infection among men living in a closed and high exposure setting. In contrast, SARS-CoV-2 infection did not statistically significantly differ between men who received oral zinc and vitamin C combination and a single dose of ivermectin compared with vitamin C. This study addressed limitations of previous studies 22-24 by incorporating serological and molecular assays without relying on subjective symptom-reporting, and by following participants for a longer duration of 42 days. Ascertaining diagnosis using laboratory methods ensures the primary outcome is not vulnerable to reporting biases and allows characterization of participants who remained asymptomatic or pauci-symptomatic throughout infection. 4, 25, 26 Prevention of infections from asymptomatic and symptomatic individuals are central to halting the spread of the virus as they are both known to transmit infection.

Our findings contrast with data from recent randomized trials, [22] [23] [24] primate studies 27 and in vitro studies using human cell lines 28 that suggested a lack of efficacy of hydroxychloroquine for SARS-CoV-2 prevention. In this study, a significant reduction in SARS-CoV-2 infection was observed in men who received a lower daily dose of hydroxychloroquine but for over a more prolonged period of 42 days. It is unclear whether these discrepant findings could be partly explained by a delay in initiating prophylaxis in previous studies (up to 6 days following a self-reported exposure) which did not allow hydroxychloroquine sufficient time to exert a prophylactic effect. By contrast, the longer prophylaxis in the current study ensured a higher cumulative level of hydroxychloroquine J o u r n a l P r e -p r o o f was achieved. Interestingly, more men had concerns for adverse effects and were advised by their friends and family members to discontinue hydroxychloroquine despite experiencing fewer adverse events. Consistent with previous trials, 22-24 we did not observe clinically apparent cardiac effects that have been reported following acute treatment, [29] [30] [31] or subclinical changes in electrocardiographic corrected QT measurements. It is also unclear, however, whether screening out men with abnormal blood pressure or electrocardiogram would have skewed selection of healthier men in the hydroxychloroquine group and inadvertently excluded those who might be more prone to cardiac effects of the drug. This study while limited in its generalizability does suggest that the question of the benefits of hydroxychloroquine in prophylaxis in certain settings

has not yet been conclusively settled.

The study is novel in that it includes topical therapy in the form of povidone-iodine administration by throat spray which lowered SARS-CoV-2 infection by 24% compared with vitamin C. These findings support in vitro data that suggest potent virucidal effects of povidone-iodine against SARS-CoV-2, 9, 10 The study has several limitations. First, we did not reflect the trial's clusterrandomized design when deriving sample sizes as the degree of clustering was unknown a priori, and thus probably underprojected the number of clusters and subjects needed to detect differences between intervention groups. The additional exclusion criteria in the hydroxychloroquine arm resulted in fewer number of eligible participants in this arm which could undermine the balancing property of randomization between medication groups.

Second, it is arguable whether vitamin C was a suitable comparator and whether a placebo pill could serve as a better control. We decided against administering placebo as this would have undermined recruitment in the placebo arm given the open-label trial design as well as the ethical legitimacy of administering placebo pills in an outbreak setting. Third, we studied only young to middle-aged men with fewer comorbidities (e.g. hypertension, hyperlipidemia etc) living in a dormitory which could explain the milder disease and apparent lack of pneumonia, thereby limiting generalizability of our findings.

Fourth, despite active measures in the dormitory to enforce NPIs, we did not assess compliance to social distancing, personal hand hygiene and mask-wearing although it is unlikely that a significant variation would occur as the study was performed in a single dormitory with uniform infrastructure and supplies and strict policing by security personnel.

Fifth, for resource, microbiological and logistical reasons, we did not perform nasopharyngeal swabs for the entire cohort and therefore could not exclude the possibility J o u r n a l P r e -p r o o f that some participants could harbor asymptomatic infection on recruitment. Diagnosing asymptomatic infection, however, can be challenging as the sensitivity of quantitative PCR could be as low as 30% in asymptomatic individuals depending on whether the test is performed during the incubation, presymptomatic or recovery phases of disease. 32, 33 To further improve its accuracy, repeated PCR tests may be required. Similarly, the ability to mount an antibody response differs between individuals and a delay in response could lead to a false-negative result. However, the impact of such variability is minimized by standardizing the timing of blood taking (baseline and day 42) across the different medication arms. Sixth, heterogeneity in exposure to infectious pathogens is difficult to control for in human trials. In this study, adjusting for different surrogates of exposure (room exposure and baseline seropositivity on the different floors) did not alter our primary findings.

Vulnerable settings where transmission can go unchecked have been clearly identified throughout the pandemic. In such settings implementing NPIs may be very challenging and there is a pressing need for additional means to prevent spread. Such settings include cruise ships, prisons, refugee camps and meat processing facilities. This is the first study to demonstrate the benefits of prophylactic therapy with either oral hydroxychloroquine or povidone-iodine throat spray in reducing SARS-CoV-2 infection among quarantined individuals living in a closed and high exposure setting. These pharmacotherapies could be used to complement existing NPIs in settings where transmission is high while awaiting roll out of a vaccine. Further research could analyze the effects in older people and women, and in those with immune compromise and other significant comorbidities, over more prolonged periods of time.

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Temasek Foundation, Singapore. Dr Tambyah reported receiving grants from Johnson and Johnson, GlaxoSmithKline and Roche.

Temasek Foundation, Singapore. Dr Tambyah reported receiving grants from Johnson and Johnson, GlaxoSmithKline and Roche. were excluded. A further 849 individuals who met the eligibility criteria were excluded as they were recruited from non-randomized floors; participants from hydroxychloroquine and ivermectin assigned floors who met additional study exclusions and received vitamin C formed part of the 849 excluded individuals. Overall, 40 clusters were randomized in equal ratios to receive the different interventions, involving 3,408 men. In the hydroxychloroquine arm, 48 were excluded due to baseline seropositivity, and 1 withdrew from the study; data from the remaining 432 participants who received hydroxychloroquine were included in the primary analysis. In the ivermectin arm, 88 were excluded due to baseline seropositivity and 4 participants withdrew from the study; the remaining 617 participants were included in the primary analysis for ivermectin. In the povidone-iodine arm, of the 863 participants who were randomized, 125 were excluded due to baseline seropositivity and 3 participants withdrew from the study; the remaining 735 participants were included in the primary analysis for povidone-iodine. In the zinc/vitamin C arm, of the 692 participants who were randomized, 56 were excluded due to baseline seropositivity and 2 participants withdrew from the study; the remaining 634 participants were included in the primary analysis for zinc/vitamin C. In the vitamin C arm, of the 663 participants who were randomized, 42 were excluded due to baseline seropositivity and 2 participants withdrew from the study; the remaining 619 participants were included in the primary analysis for vitamin C.

J o u r n a l P r e -p r o o f 

Deaths 0 (0%) -0 (0%) -0 (0%) -0 (0%) -0 (0%) J o u r n a l P r e -p r o o f 

with and without adjusting for confounders. Random effects at the cluster level are included together with fixed effects for the tabulated variables. Model 1 incorporates each cluster as a random effect within a mixed effect logistic regression. Model 2 additionally includes exposure at the beginning of the trial. The Bonferroni corrected alpha is 0.0125; tests significant at that level are starred. Confidence intervals are calculated at 98.75% to match the Bonferroni corrected alpha. Model 3 accounts for age group; Model 4 for nationality, Model 5 for compliance to medication; and Model 6 for baseline seroprevalence among other men in the same cluster. Confidence intervals are obtained through adaptive Gauss-Hermite quadrature to integrate over the space of random effects; p-values are derived from asymptotic Wald tests under the assumption that the likelihood surface is approximately Gaussian. These assumptions differ and thus the p-values and confidence intervals are not wholly in agreement. Table 5 . Participant-reported adherence and side effects. a Medication adherence was assessed in participants during the final visit using an objective adherence score that was verified by counting the remaining pills, and compared between intervention groups. Participants who were isolated in outside facilities after being diagnosed with COVID-19 and who were not able to reproduce the medication package for pill-counting were excluded from adherence analysis. Reasons for suboptimal adherence was collected from participants who reported <70% adherence to trial prophylaxis. b Information on side effects was collected by surveying daily symptoms of participants during the 42-day trial using a FormSG mobile application. Participants who were not present during the final visit and who reported <30% times in their symptom diary were excluded from side effect analysis. 

Interrupting transmission of COVID-19: lessons from containment efforts in Singapore

Epidemiological and Clinical Predictors of COVID-19

COVID-19 and Singapore: From Early Response to Circuit Breaker

Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro

From Hydroxychloroquine to Ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?

The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro

Povidone-Iodine Demonstrates Rapid In Vitro Virucidal Activity Against SARS-CoV-2, The Virus Causing COVID-19

In Vitro Efficacy of a Povidone-Iodine Nasal Antiseptic for Rapid Inactivation of SARS-CoV-2

Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture

Rapid review protocol: Zinc for the prevention or treatment of COVID-19 and other coronavirus-related respiratory tract infections

Singapore's Pandemic Preparedness: An Overview of the First Wave of COVID-19

COVID-19): The Singapore Experience. A Review of the First Eight Months

Health equity considerations in COVID-19: geospatial network analysis of the COVID-19 outbreak in the migrant population in Singapore

Singapore Ministry of Health

RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

R: A language and environment for statistical computing. R Foundation for Statistical Computing

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19

Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers: A Randomized Clinical Trial

A Cluster-Randomized Trial of Hydroxychloroquine for Prevention of Covid-19

Comparative analysis of symptomatic and asymptomatic SARS-CoV-2 infection in children

Asymptomatic SARS Coronavirus 2 infection: Invisible yet invincible

Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates

Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2

Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State

Hydroxychloroquine use in COVID-19: is the risk of cardiovascular toxicity justified?

Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports

Detection of SARS-CoV-2 RNA in nasopharyngeal swabs from COVID-19 patients and asymptomatic cases of infection by real-time and digital PCR

39) 0.66 (0.48, 0.88) Zinc and Vitamin C

J o u r n a l P r e -p r o o f